Literature DB >> 8551223

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

P S Foster1, S P Hogan, A J Ramsay, K I Matthaei, I G Young.   

Abstract

Airways inflammation is thought to play a central role in the pathogenesis of asthma. However, the precise role that individual inflammatory cells and mediators play in the development of airways hyperreactivity and the morphological changes of the lung during allergic pulmonary inflammation is unknown. In this investigation we have used a mouse model of allergic pulmonary inflammation and interleukin (IL) 5-deficient mice to establish the essential role of this cytokine and eosinophils in the initiation of aeroallergen-induced lung damage and the development of airways hyperreactivity. Sensitization and aerosol challenge of mice with ovalbumin results in airways eosinophilia and extensive lung damage analogous to that seen in asthma. Aeroallergen-challenged mice also display airways hyperreactivity to beta-methacholine. In IL-5-deficient mice, the eosinophilia, lung damage, and airways hyperreactivity normally resulting from aeroallergen challenge were abolished. Reconstitution of IL-5 production with recombinant vaccinia viruses engineered to express this factor completely restored aeroallergen-induced eosinophilia and airways dysfunction. These results indicate that IL-5 and eosinophils are central mediators in the pathogenesis of allergic lung disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551223      PMCID: PMC2192412          DOI: 10.1084/jem.183.1.195

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

Review 1.  Macrophages and polymorphonuclear neutrophils in lung defense and injury.

Authors:  Y Sibille; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1990-02

2.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity.

Authors:  A J Wardlaw; S Dunnette; G J Gleich; J V Collins; A B Kay
Journal:  Am Rev Respir Dis       Date:  1988-01

3.  Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice.

Authors:  R L Coffman; B W Seymour; S Hudak; J Jackson; D Rennick
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

Review 4.  The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity.

Authors:  G J Gleich; N A Flavahan; T Fujisawa; P M Vanhoutte
Journal:  J Allergy Clin Immunol       Date:  1988-05       Impact factor: 10.793

5.  IgE and eosinophil regulation in a murine model of allergic aspergillosis.

Authors:  V P Kurup; H Choi; P S Murali; R L Coffman
Journal:  J Leukoc Biol       Date:  1994-11       Impact factor: 4.962

6.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions.

Authors:  J G De Monchy; H F Kauffman; P Venge; G H Koëter; H M Jansen; H J Sluiter; K De Vries
Journal:  Am Rev Respir Dis       Date:  1985-03

7.  Cellular events in the bronchi in mild asthma and after bronchial provocation.

Authors:  R Beasley; W R Roche; J A Roberts; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1989-03

8.  Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5).

Authors:  H D Campbell; W Q Tucker; Y Hort; M E Martinson; G Mayo; E J Clutterbuck; C J Sanderson; I G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

10.  Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor.

Authors:  Y Yamaguchi; Y Hayashi; Y Sugama; Y Miura; T Kasahara; S Kitamura; M Torisu; S Mita; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  292 in total

Review 1.  Genes that regulate eosinophilic inflammation.

Authors:  D H Broide; H Hoffman; P Sriramarao
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 3.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  Airway hyperresponsiveness in asthma: not just a matter of airway inflammation.

Authors:  V Brusasco; E Crimi; R Pellegrino
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 5.  Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs.

Authors:  P G Holt; P D Sly
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 6.  Interleukin-5, a therapeutic target in allergic inflammation.

Authors:  D P Huston; M M Huston; R R Dickason; M Martinez-Moczygemba
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

7.  Eosinophilic venulitis in the small intestines in a mouse model of late asthma.

Authors:  Linh Kan Bui; Toshiharu Hayashi; Tomomi Nakashima; Yoichiro Horii
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

Review 8.  Biology of the eosinophil.

Authors:  Carine Blanchard; Marc E Rothenberg
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

9.  Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma.

Authors:  Masato Komai; Hiroyuki Tanaka; Taisei Masuda; Koichi Nagao; Masayuki Ishizaki; Masatsugu Sawada; Hiroichi Nagai
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  Role of metalloelastase in a model of allergic lung responses induced by cockroach allergen.

Authors:  Roscoe L Warner; Nicholas W Lukacs; Steven D Shapiro; Narasimharao Bhagarvathula; Kamalakar C Nerusu; James Varani; Kent J Johnson
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.